Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Hepatitis C subtype distribution in chronically infected patients with mild liver fibrosis in France: the GEMHEP study.

Semenova T, Nemoz B, Thibault V, Lagathu G, Duverlie G, Brochot E, Trimoulet P, Payan C, Vallet S, Henquell C, Chevaliez S, Bouvier-Alias M, Maylin S, Roque-Afonso AM, Izquierdo L, Lunel-Fabiani F, Marcellin P, Morand P, Leroy V, Larrat S.

Epidemiol Infect. 2019 Jan;147:e234. doi: 10.1017/S0950268819001225.

2.

Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients.

Salmon D, Trimoulet P, Gilbert C, Solas C, Lafourcade E, Chas J, Piroth L, Lacombe K, Katlama C, Peytavin G, Aumaitre H, Alric L, Boué F, Morlat P, Poizot-Martin I, Billaud E, Rosenthal E, Naqvi A, Miailhes P, Bani-Sadr F, Esterle L, Carrieri P, Dabis F, Sogni P, Wittkop L; ANRS CO13 Hepavih study Group.

World J Hepatol. 2018 Nov 27;10(11):856-866. doi: 10.4254/wjh.v10.i11.856.

3.

The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro.

Salpini R, Surdo M, Cortese MF, Palumbo GA, Carioti L, Cappiello G, Spanò A, Trimoulet P, Fleury H, Vecchiet J, Pasquazzi C, Mirabelli C, Scutari R, Sacco A, Alkhatib M, Missale G, Francioso S, Sarmati L, Andreoni M, Angelico M, Ceccherini-Silberstein F, Levrero M, Perno CF, Belloni L, Svicher V.

Clin Microbiol Infect. 2019 Jul;25(7):906.e1-906.e7. doi: 10.1016/j.cmi.2018.11.017. Epub 2018 Nov 23.

PMID:
30472417
4.

HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets.

Colagrossi L, Salpini R, Scutari R, Carioti L, Battisti A, Piermatteo L, Bertoli A, Fabeni L, Minichini C, Trimoulet P, Fleury H, Nebuloso E, De Cristofaro M, Cappiello G, Spanò A, Malagnino V, Mari T, Barlattani A, Iapadre N, Lichtner M, Mastroianni C, Lenci I, Pasquazzi C, De Sanctis GM, Galeota Lanza A, Stanzione M, Stornaiuolo G, Marignani M, Sarmati L, Andreoni M, Angelico M, Ceccherini-Silberstein F, Perno CF, Coppola N, Svicher V.

Viruses. 2018 Jul 9;10(7). pii: E363. doi: 10.3390/v10070363.

5.

Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe.

Colagrossi L, Hermans LE, Salpini R, Di Carlo D, Pas SD, Alvarez M, Ben-Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dyda T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar MM, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Lepej SZ, Weis N, Yalcinkaya T, Boucher CAB, Wensing AMJ, Perno CF, Svicher V; HEPVIR working group of the European Society for translational antiviral research (ESAR).

BMC Infect Dis. 2018 Jun 1;18(1):251. doi: 10.1186/s12879-018-3161-2.

6.

A European multicenter study on the analytical performance of the VERIS HBV assay.

Braun P, Delgado R, Drago M, Fanti D, Fleury H, Izopet J, Lombardi A, Mancon A, Marcos MA, Sauné K, O Shea S, Pérez-Rivilla A, Ramble J, Trimoulet P, Vila J, Whittaker D, Artus A, Rhodes D.

J Clin Virol. 2018 Feb - Mar;99-100:50-56. doi: 10.1016/j.jcv.2017.12.009. Epub 2017 Dec 19.

PMID:
29328964
7.

Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world.

Halfon P, Scholtès C, Izopet J, Larrat S, Trimoulet P, Zoulim F, Alric L, Métivier S, Leroy V, Ouzan D, de Lédinghen V, Mohamed S, Pénaranda G, Khiri H, Thélu MA, Plauzolles A, Chiche L, Bourlière M, Abravanel F.

J Hepatol. 2018 Mar;68(3):595-597. doi: 10.1016/j.jhep.2017.09.019. Epub 2017 Oct 4. No abstract available.

PMID:
28987520
8.

A European multicientre study on the comparison of HBV viral loads between VERIS HBV assay and Roche COBAS® TAQMAN® HBV test, Abbott RealTime HBV assay, Siemens VERSANT HBV assay, and Qiagen artus HBV RG kit.

Braun P, Delgado R, Drago M, Fanti D, Fleury H, Izopet J, Lombardi A, Marcos M, Sauné K, O'Shea S, Pérez-Rivilla A, Ramble J, Trimoulet P, Vila J, Whittaker D, Artus A, Rhodes D.

J Clin Virol. 2017 Oct;95:76-83. doi: 10.1016/j.jcv.2017.08.015. Epub 2017 Sep 9.

PMID:
28892764
9.

Baseline and post-treatment hepatitis C NS5A resistance in relapsed patients from a multicentric real-life cohort.

Halfon P, Scholtès C, Izopet J, Larrat S, Trimoulet P, Zoulim F, Alric L, Métivier S, Leroy V, Ouzan D, de Lédinghen V, Mohamed S, Pénaranda G, Khiri H, Thélu MA, Plauzolles A, Chiche L, Bourlière M, Abravanel F.

Antivir Ther. 2018;23(4):307-314. doi: 10.3851/IMP3184.

PMID:
28730994
10.

A European multicientre study on the comparison of HIV-1 viral loads between VERIS HIV-1 Assay and Roche COBAS® TAQMAN® HIV-1 test, Abbott RealTime HIV-1 Assay, and Siemens VERSANT HIV-1 Assay.

Braun P, Delgado R, Drago M, Fanti D, Fleury H, Hofmann J, Izopet J, Kühn S, Lombardi A, Mancon A, Marcos MA, Mileto D, Sauné K, O'Shea S, Pérez-Rivilla A, Ramble J, Trimoulet P, Vila J, Whittaker D, Artus A, Rhodes D.

J Clin Virol. 2017 Jul;92:75-82. doi: 10.1016/j.jcv.2017.05.003. Epub 2017 May 11.

PMID:
28599228
11.

European Multicenter Study on Analytical Performance of Veris HIV-1 Assay.

Braun P, Delgado R, Drago M, Fanti D, Fleury H, Hofmann J, Izopet J, Kalus U, Lombardi A, Marcos MA, Mileto D, Sauné K, O'Shea S, Pérez-Rivilla A, Ramble J, Trimoulet P, Vila J, Whittaker D, Artus A, Rhodes DW.

J Clin Microbiol. 2017 Jul;55(7):2055-2063. doi: 10.1128/JCM.00078-17. Epub 2017 Apr 19.

12.

Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma.

Le Guillou-Guillemette H, Pivert A, Bouthry E, Henquell C, Petsaris O, Ducancelle A, Veillon P, Vallet S, Alain S, Thibault V, Abravanel F, Rosenberg AA, André-Garnier E, Bour JB, Baazia Y, Trimoulet P, André P, Gaudy-Graffin C, Bettinger D, Larrat S, Signori-Schmuck A, Saoudin H, Pozzetto B, Lagathu G, Minjolle-Cha S, Stoll-Keller F, Pawlotsky JM, Izopet J, Payan C, Lunel-Fabiani F, Lemaire C.

PLoS One. 2017 Apr 10;12(4):e0174651. doi: 10.1371/journal.pone.0174651. eCollection 2017.

13.

A European multicentre study on the comparison of HCV viral loads between VERIS HCV assay and COBAS® TaqMan® HCV Test and RealTime HCV Assay.

Braun P, Drago M, Fanti D, Fleury H, Hofmann J, Izopet J, Kühn S, Lombardi A, Micheli V, Sauné K, Trimoulet P, Whittaker D, Artus A, Rhodes D.

J Clin Virol. 2017 May;90:18-25. doi: 10.1016/j.jcv.2017.03.006. Epub 2017 Mar 9.

PMID:
28319847
14.

Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro.

Salpini R, Surdo M, Warner N, Cortese MF, Colledge D, Soppe S, Bellocchi MC, Armenia D, Carioti L, Continenza F, Di Carlo D, Saccomandi P, Mirabelli C, Pollicita M, Longo R, Romano S, Cappiello G, Spanò A, Trimoulet P, Fleury H, Vecchiet J, Iapadre N, Barlattani A, Bertoli A, Mari T, Pasquazzi C, Missale G, Sarrecchia C, Orecchini E, Michienzi A, Andreoni M, Francioso S, Angelico M, Verheyen J, Ceccherini-Silberstein F, Locarnini S, Perno CF, Svicher V.

Oncotarget. 2017 Feb 28;8(9):15704-15715. doi: 10.18632/oncotarget.14944.

15.

European Multicenter Study on Analytical Performance of DxN Veris System HCV Assay.

Braun P, Delgado R, Drago M, Fanti D, Fleury H, Gismondo MR, Hofmann J, Izopet J, Kühn S, Lombardi A, Marcos MA, Sauné K, O'Shea S, Pérez-Rivilla A, Ramble J, Trimoulet P, Vila J, Whittaker D, Artus A, Rhodes DW.

J Clin Microbiol. 2017 Apr;55(4):1186-1192. doi: 10.1128/JCM.02163-16. Epub 2017 Feb 1.

16.

Optimizing hepatitis B vaccination in prison.

Perrodeau F, Pillot-Debelleix M, Vergniol J, Lemonnier F, Receveur MC, Trimoulet P, Raymond I, Le Port G, Gromb-Monnoyeur S.

Med Mal Infect. 2016 Mar;46(2):96-9. doi: 10.1016/j.medmal.2016.01.002. Epub 2016 Feb 19.

PMID:
26905392
17.

Identification of a duplicated V3 domain in NS5A associated with cirrhosis and hepatocellular carcinoma in HCV-1b patients.

Le Guillou-Guillemette H, Ducancelle A, Bertrais S, Lemaire C, Pivert A, Veillon P, Bouthry E, Alain S, Thibault V, Abravanel F, Rosenberg AR, Henquell C, André-Garnier E, Petsaris O, Vallet S, Bour JB, Baazia Y, Trimoulet P, André P, Gaudy-Graffin C, Bettinger D, Larrat S, Signori-Schmuck A, Saoudin H, Pozzetto B, Lagathu G, Minjolle-Cha S, Stoll-Keller F, Pawlotsky JM, Izopet J, Payan C, Lunel-Fabiani F.

J Clin Virol. 2015 Aug;69:203-9. doi: 10.1016/j.jcv.2015.06.096. Epub 2015 Jun 24.

18.

Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).

Hermans LE, Svicher V, Pas SD, Salpini R, Alvarez M, Ben Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dyda T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar MM, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Weis N, Yalcinkaya T, Lepej SZ, Perno C, Boucher CA, Wensing AM; HEPVIR Working Group of the European Society for Translational Antiviral Research.

J Infect Dis. 2016 Jan 1;213(1):39-48. doi: 10.1093/infdis/jiv363. Epub 2015 Jul 1.

PMID:
26136470
19.

Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia.

Aissa Larousse J, Trimoulet P, Recordon Pinson P, Tauzin B, Azzouz MM, Ben Mami N, Cheikh I, Triki H, Fleury H.

Virol J. 2015 Jun 6;12:84. doi: 10.1186/s12985-015-0318-0.

20.

Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.

Larrat S, Vallet S, David-Tchouda S, Caporossi A, Margier J, Ramière C, Scholtes C, Haïm-Boukobza S, Roque-Afonso AM, Besse B, André-Garnier E, Mohamed S, Halfon P, Pivert A, LeGuillou-Guillemette H, Abravanel F, Guivarch M, Mackiewicz V, Lada O, Mourez T, Plantier JC, Baazia Y, Alain S, Hantz S, Thibault V, Gaudy-Graffin C, Bouvet D, Mirand A, Henquell C, Gozlan J, Lagathu G, Pronier C, Velay A, Schvoerer E, Trimoulet P, Fleury H, Bouvier-Alias M, Brochot E, Duverlie G, Maylin S, Gouriou S, Pawlotsky JM, Morand P.

J Clin Microbiol. 2015 Jul;53(7):2195-202. doi: 10.1128/JCM.03633-14. Epub 2015 Apr 29.

21.

Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection.

Mirabelli C, Surdo M, Van Hemert F, Lian Z, Salpini R, Cento V, Cortese MF, Aragri M, Pollicita M, Alteri C, Bertoli A, Berkhout B, Micheli V, Gubertini G, Santoro MM, Romano S, Visca M, Bernassola M, Longo R, De Sanctis GM, Trimoulet P, Fleury H, Marino N, Mazzotta F, Cappiello G, Spanò A, Sarrecchia C, Zhang JM, Andreoni M, Angelico M, Verheyen J, Perno CF, Svicher V.

J Infect. 2015 Mar;70(3):288-98. doi: 10.1016/j.jinf.2014.10.015. Epub 2014 Nov 6.

PMID:
25452041
22.

Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia.

Aissa Larousse J, Trimoulet P, Recordon-Pinson P, Papuchon J, Azzouz MM, Ben Mami N, Cheikh I, Triki H, Fleury H.

J Med Virol. 2014 Aug;86(8):1350-9. doi: 10.1002/jmv.23958. Epub 2014 Apr 24.

PMID:
24760718
23.

Hepatitis E virus infection as a new probable cause of de novo membranous nephropathy after kidney transplantation.

Taton B, Moreau K, Lepreux S, Bachelet T, Trimoulet P, De Ledinghen V, Pommereau A, Ronco P, Kamar N, Merville P, Couzi L.

Transpl Infect Dis. 2013 Dec;15(6):E211-5. doi: 10.1111/tid.12143. Epub 2013 Sep 18.

PMID:
24103101
24.

Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy.

Trimoulet P, Pinson P, Papuchon J, Foucher J, Vergniol J, Chermak F, Wittkop L, Castaing N, Merrouche W, Reigadas S, Molimard M, Kann M, Fleury H, de Lédinghen V.

Antivir Ther. 2013;18(5):723-7. doi: 10.3851/IMP2632. Epub 2013 May 23.

PMID:
23702639
25.

Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study.

Thibault V, Gaudy-Graffin C, Colson P, Gozlan J, Schnepf N, Trimoulet P, Pallier C, Saune K, Branger M, Coste M, Thoraval FR; ANRS Multivir-HBV group.

Virol J. 2013 Mar 15;10:87. doi: 10.1186/1743-422X-10-87.

26.

Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping.

Vallet S, Larrat S, Laperche S, Le Guillou-Guillemette H, Legrand-Abravanel F, Bouchardeau F, Pivert A, Henquell C, Mirand A, André-Garnier E, Giordanengo V, Lagathu G, Thibault V, Scholtes C, Schvoerer E, Gaudy-Graffin C, Maylin S, Trimoulet P, Brochot E, Hantz S, Gozlan J, Roque-Afonso AM, Soussan P, Plantier JC, Charpentier C, Chevaliez S, Colson P, Mackiewicz V, Aguilera L, Rosec S, Gouriou S, Magnat N, Lunel-Fabiani F, Izopet J, Morand P, Payan C, Pawlotsky JM.

J Clin Microbiol. 2013 May;51(5):1428-33. doi: 10.1128/JCM.03032-12. Epub 2013 Feb 20.

27.

HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patients.

Abravanel F, Raymond S, Pambrun E, Winnock M, Bonnard P, Sogni P, Trimoulet P, Dabis F, Salmon-Ceron D, Izopet J; ANRS CO13 HEPAVIH Study Group.

PLoS One. 2012;7(11):e50289. doi: 10.1371/journal.pone.0050289. Epub 2012 Nov 30.

28.

Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).

Couzigou P, Pérusat S, Bourlière M, Trimoulet P, Poynard T, Leroy V, Marcellin P, Foucher J, Bronowicki JP, Chêne G; ANRS HC16 GAMMATRI Trial Group.

J Gastroenterol Hepatol. 2013 Feb;28(2):329-34. doi: 10.1111/jgh.12060.

PMID:
23190183
29.

Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution.

Cento V, Mirabelli C, Dimonte S, Salpini R, Han Y, Trimoulet P, Bertoli A, Micheli V, Gubertini G, Cappiello G, Spanò A, Longo R, Bernassola M, Mazzotta F, De Sanctis GM, Zhang XX, Verheyen J, D'Arminio Monforte A, Ceccherini-Silberstein F, Perno CF, Svicher V.

J Gen Virol. 2013 Jan;94(Pt 1):143-9. doi: 10.1099/vir.0.046524-0. Epub 2012 Oct 10.

PMID:
23052389
30.

Hepatitis C virus RNA quantitation in a nationwide French cohort of patients co-infected with HIV and HCV: should the same test be applied to all samples?

Trimoulet P, Merchadou L, Winnock M, Loko MA, Fleury H, Salmon D, Dabis F, Neau D; ANRS CO 13 HEPAVIH Study Group.

J Virol Methods. 2012 Apr;181(1):131-3. doi: 10.1016/j.jviromet.2012.01.006. Epub 2012 Jan 20.

PMID:
22285372
31.

NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.

Vallet S, Viron F, Henquell C, Le Guillou-Guillemette H, Lagathu G, Abravanel F, Trimoulet P, Soussan P, Schvoerer E, Rosenberg A, Gouriou S, Colson P, Izopet J, Payan C; ANRS AC11 HCV Group.

Antivir Ther. 2011;16(7):1093-102. doi: 10.3851/IMP1900.

PMID:
22024525
32.

Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development.

Svicher V, Cento V, Salpini R, Mercurio F, Fraune M, Beggel B, Han Y, Gori C, Wittkop L, Bertoli A, Micheli V, Gubertini G, Longo R, Romano S, Visca M, Gallinaro V, Marino N, Mazzotta F, De Sanctis GM, Fleury H, Trimoulet P, Angelico M, Cappiello G, Zhang XX, Verheyen J, Ceccherini-Silberstein F, Perno CF.

Dig Liver Dis. 2011 Dec;43(12):975-83. doi: 10.1016/j.dld.2011.07.002. Epub 2011 Aug 9.

PMID:
21831732
33.

Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients.

Trimoulet P, Belzunce C, Faure M, Wittkop L, Reigadas S, Dupon M, Ragnaud JM, Fleury H, Neau D.

HIV Med. 2011 Sep;12(8):506-9. doi: 10.1111/j.1468-1293.2011.00913.x. Epub 2011 Mar 16.

34.

Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study.

Henquell C, Guglielmini J, Verbeeck J, Mahul A, Thibault V, Lebray P, Laperche S, Trimoulet P, Foucher J, Le Guillou-Guillemette H, Fouchard-Hubert I, Legrand-Abravanel F, Métivier S, Gaudy C, D'Alteroche L, Rosenberg AR, Podevin P, Plantier JC, Riachi G, Saoudin H, Coppere H, André E, Gournay J, Feray C, Vallet S, Nousbaum JB, Baazia Y, Roulot D, Alain S, Loustaud-Ratti V, Schvoerer E, Habersetzer F, Pérez-Serra RJ, Gourari S, Mirand A, Odent-Malaure H, Garraud O, Izopet J, Bommelaer G, Peigue-Lafeuille H, van Ranst M, Abergel A, Bailly JL.

Infect Genet Evol. 2011 Mar;11(2):496-503. doi: 10.1016/j.meegid.2010.12.015. Epub 2011 Jan 18.

PMID:
21251997
35.

Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.

Castéra L, Bernard PH, Le Bail B, Foucher J, Trimoulet P, Merrouche W, Couzigou P, de Lédinghen V.

Aliment Pharmacol Ther. 2011 Feb;33(4):455-65. doi: 10.1111/j.1365-2036.2010.04547.x.

36.

Interpretation of real-time PCR results for hepatitis C virus RNA when viral load is below quantification limits.

Laperche S, Bouchardeau F, André-Garnier E, Thibault V, Roque-Afonso AM, Trimoulet P, Colimon R, Duverlie G, Leguillou-Guillemette H, Lunel F, Bouvier-Alias M, Pawlotsky JM, Henquell C, Schvoerer E, Stoll-Keller F, Chaix ML, Branger M, Gaudy-Graffin C, Rosenberg AR, Pozzetto B, Vallet S, Baazia Y, Izopet J, Lefrère JJ.

J Clin Microbiol. 2011 Mar;49(3):1113-5. doi: 10.1128/JCM.01511-10. Epub 2011 Jan 12.

37.

Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).

Halfon P, Pérusat S, Bourlière M, Bronowicki JP, Trimoulet P, Benhamou Y, Leroy V, Marcellin P, Foucher J, Penaranda G, Chêne G, Couzigou P; ANRS HC16 GAMMATRI Study Group.

J Med Virol. 2010 Dec;82(12):2027-31. doi: 10.1002/jmv.21909.

PMID:
20981789
38.

Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients.

Breilh D, Djabarouti S, Trimoulet P, Le Bail B, Dupon M, Ragnaud JM, Fleury H, Saux MC, Thiébaut R, Chêne G, Neau D.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):428-30. doi: 10.1097/QAI.0b013e3181b62858. No abstract available.

PMID:
19858925
39.

Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy.

Legrand-Abravanel F, Colson P, Leguillou-Guillemette H, Alric L, Ravaux I, Lunel-Fabiani F, Bouviers-Alias M, Trimoulet P, Chaix ML, Hézode C, Foucher J, Fontaine H, Roque-Afonso AM, Gassin M, Schvoerer E, Gaudy C, Roche B, Doffoël M, D'Alteroche L, Vallet S, Baazia Y, Pozzetto B, Thibault V, Nousbaum JB, Roulot D, Coppere H, Poynard T, Payan C, Izopet J.

J Med Virol. 2009 Dec;81(12):2029-35. doi: 10.1002/jmv.21583. Erratum in: J Med Virol. 2010 Sep;82(9):1627. Poinard, Thierry [corrected to Poynard, Thierry].

40.

Re-evaluation of anti-HBc non-reactive serum samples from patients with persistent hepatitis B infection by immune precipitation with labelled HBV core antigen.

Kantelhardt VC, Schwarz A, Wend U, Schüttler CG, Willems WR, Trimoulet P, Fleury H, Gerlich WH, Kann M.

J Clin Virol. 2009 Oct;46(2):124-8. doi: 10.1016/j.jcv.2009.06.018. Epub 2009 Jul 24.

PMID:
19631583
41.

Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C.

Breilh D, Foucher J, Castéra L, Trimoulet P, Djabarouti S, Merrouche W, Couzigou P, Saux MC, de Lédinghen V.

Aliment Pharmacol Ther. 2009 Sep 1;30(5):487-94. doi: 10.1111/j.1365-2036.2009.04065.x. Epub 2009 Jun 11.

42.

Evolution of plasma hepatitis C virus load in patients coinfected by HIV and hepatitis C Virus started on a protease inhibitor-containing antiretroviral regimen, Agence Nationale de Recherches sur le SIDA CO8 APROCO-COPILOTE cohort.

Neau D, Trimoulet P, Pereira E, Lafon ME, Gervais A, Ragnaud JM, Dupon M, Ecobichon JL, Chêne G, Raffi F; ANRS CO8 APROCO-COPILOTE Study Group.

J Acquir Immune Defic Syndr. 2008 Jun 1;48(2):227-9. doi: 10.1097/QAI.0b013e31816d9cc3. No abstract available.

PMID:
18520685
43.

Hepatitis B virus genotypes: a retrospective survey in Southwestern France, 1999-2004.

Trimoulet P, Boutonnet M, Winnock M, Faure M, Loko MA, De Lédinghen V, Bernard PH, Castéra L, Foucher J, Dupon M, Ragnaud JM, Lafon ME, Couzigou P, Dabis F, Fleury H, Neau D.

Gastroenterol Clin Biol. 2007 Dec;31(12):1088-94.

44.

Seven nucleotide changes characteristic of the hepatitis C virus genotype 3 5' untranslated region: correlation with reduced in vitro replication.

Masante C, Mahias K, Lourenço S, Dumas E, Cahour A, Trimoulet P, Fleury H, Astier-Gin T, Ventura M.

J Gen Virol. 2008 Jan;89(Pt 1):212-21.

PMID:
18089745
45.

Multicenter trials need to use the same assay for hepatitis C virus viral load determination.

Laperche S, Bouchardeau F, Thibault V, Pozzetto B, Vallet S, Rosenberg AR, Roque-Afonso AM, Gassin M, Stoll-Keller F, Trimoulet P, Gault E, Chanzy B, Mercier B, Branger M, Pawlotsky JM, Henquell C, Lunel F, Gaudy-Graffin C, Alain S, Chaix ML, Duverlie G, Izopet J, Lefrère JJ.

J Clin Microbiol. 2007 Nov;45(11):3788-90. Epub 2007 Oct 3.

46.

Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype.

Castéra L, Loko MA, Le Bail B, Coffie P, De Ledinghen V, Trimoulet P, Winnock M, Dabis F, Neau D; Groupe D'epidémiologie Clinique du Sida en Aquitaine (GECSA).

Aliment Pharmacol Ther. 2007 Dec;26(11-12):1489-98. Epub 2007 Sep 28.

47.

Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow-up of 196 patients (4535 patient-years).

de Lédinghen V, Trimoulet P, Mannant PR, Dumas F, Champbenoît P, Baldit C, Foucher J, Faure M, Vergniol J, Castéra L, Bertet J, Fleury H, Couzigou P, Bernard PH.

J Hepatol. 2007 Jan;46(1):19-25. Epub 2006 Sep 22.

PMID:
17030451
48.

Estimation of dynamical model parameters taking into account undetectable marker values.

Thiébaut R, Guedj J, Jacqmin-Gadda H, Chêne G, Trimoulet P, Neau D, Commenges D.

BMC Med Res Methodol. 2006 Aug 1;6:38.

49.

Plasma and liver hepatitis C virus variability in patients coinfected with human immunodeficiency virus.

Jouvencel AC, Neau D, Faure M, Neau M, Martinaud C, Legrand E, Trimoulet P, Garrigue I, Le Bail B, Bioulac-Sage P, Dupon M, Ragnaud JM, Fleury H, Lafon ME.

J Clin Microbiol. 2006 May;44(5):1877-80.

50.

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.

Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, Rozenbaum W, Le Teuff G, Trylesinski A, Piketty C; TECOVIR Study Group.

Hepatology. 2006 Mar;43(3):548-55.

PMID:
16496322

Supplemental Content

Loading ...
Support Center